Teva Pharmaceutical Industries Ltd.'s new CEO Kåre Schultz has established a solid track record in the short time he's been overseeing the rationalization of Danish neurology drug specialist Lundbeck Inc. Whether he can replicate the same success at a very different kind of company – the world's biggest generic drug company – is now the question.
Lundbeck's share price has more than tripled during his time as CEO of the company, with sales rising by a healthy 16% in those two years (as of the end of 2016) and profits, margins and cash flow restored to vitality
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?